Your browser doesn't support javascript.
loading
Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study.
Erdem, Rahsan; De Coster, Ilse; Withanage, Kanchanamala; Mercer, Laina D; Marchant, Arnaud; Taton, Martin; Cools, Nathalie; Lion, Eva; Cassels, Fred; Higgins, Deborah; Ivinson, Karen; Locke, Emily; Mahmood, Kutub; Wright, Peter F; Gast, Chris; White, Jessica A; Ackerman, Margaret E; Konopka-Anstadt, Jennifer L; Mainou, Bernardo A; Van Damme, Pierre.
Afiliación
  • Erdem R; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA.
  • De Coster I; Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Edegem, Belgium. Electronic address: ilse.decoster@uantwerpen.be.
  • Withanage K; Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Edegem, Belgium.
  • Mercer LD; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA.
  • Marchant A; Institute for Medical Immunology, Université libre de Bruxelles, Brussels, Belgium.
  • Taton M; Institute for Medical Immunology, Université libre de Bruxelles, Brussels, Belgium.
  • Cools N; Vaccine & Infectious Disease Institute, Laboratory of Experimental Hematology, University of Antwerp, Wilrijk, Belgium.
  • Lion E; Vaccine & Infectious Disease Institute, Laboratory of Experimental Hematology, University of Antwerp, Wilrijk, Belgium.
  • Cassels F; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA.
  • Higgins D; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA.
  • Ivinson K; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA.
  • Locke E; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA.
  • Mahmood K; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA.
  • Wright PF; Dartmouth College, Lebanon, NH, USA.
  • Gast C; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA.
  • White JA; PATH, Center for Vaccine Innovation and Access, Seattle, WA, USA.
  • Ackerman ME; Dartmouth College, Lebanon, NH, USA.
  • Konopka-Anstadt JL; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Mainou BA; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Van Damme P; Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Edegem, Belgium.
Vaccine ; 41(10): 1657-1667, 2023 03 03.
Article en En | MEDLINE | ID: mdl-36746739
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Poliomielitis / Vacuna Antipolio de Virus Inactivados Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Vaccine Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Poliomielitis / Vacuna Antipolio de Virus Inactivados Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Vaccine Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos